2019 Archived Content

BUZZ Sessions

8:00 - 9:00 AM

Facilitated, small-group discussions. Interactive participation leads to problem-solving solutions and future collaborations around focused topics.

Protein therapeutics is a fast-growing global market. As the science improves, so does the complexity of the R&D organization. Ensuring product quality plus speed to market requires insights from stakeholders working across the stages of protein science R&D. Join experts representing the PepTalk pipelines, peers, and colleagues for an interactive roundtable discussion. Topics include highlights from the week’s presentations, new technologies and strategies, challenges, and future trends.

To see discussion table topics for the Monday BuzZ Sessions with Refreshments (January 14 at 3:15 - 4:30 pm), please click here.

Discussion Table Topics

Protein Engineering & Development – Week in Review

Sam Wu, PhD, Principal Scientist, Janssen BioTherapeutics

  • What were your favorite presentations this week?
  • How will the new constructs and technologies presented at PepTalk impact your work?
  • What are the challenges to be overcome in implementing these new approaches?
  • Emerging trends that will impact protein engineering and development

B Cell and T Cell Repertoire Screening Technology

Vu Truong, PhD, CSO & CEO, R&D, Aridis Pharmaceuticals, Inc.

  • Technical barriers
  • Size of B cell repertoire, human vs. mouse
  • Current approaches
  • Pre-select target or no?
  • Rapid antibody generation and production

Antibody Therapeutics – Weekly Wrap-Up

Rakesh Dixit, PhD, DABT, Vice President, Medimmune-AstraZeneca

  • The latest breakthroughs in cancer immunotherapies
  • Combination therapies
  • Antibody-Drug Conjugates
  • What is happening in bispecific and multi-specific antibodies

Rational Formulation Design, Optimization, Analytics and Development – Week in Review

Thomas Laue, PhD, Professor Emeritus, Molecular, Cellular and Biomedical Sciences, University of New Hampshire

  • What were your favorite talks and what information about your molecule did you seek that will help you?
  • What experiments can you do to focus your design choices for liquid or lyophilized or other novel formulations?
  • Most critical and useful analytical techniques you learned about from the talks in the analytics and impurities conferences
  • Are there topics that were not covered adequately?
  • What are the critical needs to advance formulation design?

Process Technologies and Purification – Weekly Wrap-Up

David Wood, PhD, Professor, Chemical & Biomolecular Engineering, The Ohio State University

  • The best techniques and strategies for managing data
  • How high-throughput technologies put greater demands on data management
  • The best approaches for controlling bioprocesses
  • How new technologies are affecting downstream processes

Biotherapeutic Expression & Production Pipeline – Week in Review

Richard Altman, MS, Scientist, Protein Technologies, Amgen

Recombinant protein production continues its rapid evolution as a critical part of the biotherapeutic drug discovery process. We review the highlights from the Biotherapeutic Expression & Production Pipeline with a focus on the “Recombinant Protein Expression and Purification” and “Optimizing Expression Platforms” conferences. We discuss the following in an interactive roundtable environment:

  • Highlights from the week’s presentations
    • New technologies and strategies
  • With these new technologies, how do we increase not only the efficiency and throughput of recombinant protein expression, but of the entire protein production process?
  • Challenges and future trends

Alternative Expression & Products – The Week’s Highlights

Suresh Kumar Thallapuranam, PhD, Professor, Department of Chemistry & Biochemistry, University of Arkansas

  • Current challenges in microbial production
  • Scaling up and controlling a microbial process 
  • Emerging microbial platforms, modalities and applications
  • Application of Synthetic biology 
  • How do microbial departments vary across companies, how to maximize collaboration